Recent Posts
Deals•Feb 19, 2026
Altesa Raises $75M for Oral Respiratory Med
Altesa announced a $75 million fundraising round to develop its oral respiratory medication. The capital will support further clinical development and commercialization efforts.
Endpoints News
Deals•Feb 18, 2026
Faeth Goes Public via Merger with Sensei, Raising $200M
Faeth announced its public listing through a merger with Sensei, generating $200 million from a stock sale. The transaction marks Faeth's entry into the public markets.
Endpoints News
Deals•Feb 17, 2026
Six Biotech Companies File for HKEX IPOs
Six biotechnology firms have filed for initial public offerings on the Hong Kong Stock Exchange, signaling a push into Asian capital markets. The filings were announced on February 17, 2026.
Endpoints News
Deals•Feb 13, 2026
Gilead Acquires Global Rights to Genhouse Bio's Oral Cancer Drug for $80M
Gilead announced it will acquire the global rights to an oral cancer drug from China-based biotech Genhouse Bio, paying $80 million upfront. The deal expands Gilead's oncology pipeline as Genhouse prepares for a Hong Kong IPO.
Endpoints News
Deals•Feb 10, 2026
Cascade Pharmaceuticals Raises $72M to Develop MASH, Obesity and Diabetes Drugs
Shanghai-based biotech Cascade Pharmaceuticals announced it has secured $72 million (about 500 million yuan) in new funding to advance its pipeline targeting metabolic-associated steatohepatitis (MASH), obesity, and diabetes. The capital will support preclinical and clinical development of its drug candidates.
Endpoints News
Deals•Feb 10, 2026
ILiAD Biotechnologies Secures $115M Series B to Advance Whooping Cough Vaccine
ILiAD Biotechnologies announced an oversubscribed $115 million Series B financing on Tuesday. The new capital will fund pivotal Phase 3 trials for its whooping cough vaccine, accelerating development and potential market entry.
Endpoints News
Deals•Feb 9, 2026
QuantX Biosciences Secures $85M Series B Funding Led by Lilly and Sanofi Ventures
China‑American biotech QuantX Biosciences announced a $85 million Series B round, led by the venture arms of Eli Lilly and Sanofi. The funding will accelerate its immunology pipeline targeting key immune‑related diseases. The round highlights strong investor interest in biotech innovations.
Endpoints News
Deals•Feb 6, 2026
Agomab Therapeutics and SpyGlass Pharma Set to IPO on Friday
Fibrosis‑focused Agomab Therapeutics and eye‑disease company SpyGlass Pharma announced they will go public on Friday, marking a significant week for biotech IPOs. The offerings are expected to boost the biotech sector's comeback after a slowdown.
Endpoints News
Deals•Feb 5, 2026
Veradermics Surges 122% on Debut as Biotech Goes Public
Biotech firm Veradermics, developing an oral form of Rogaine, completed its initial public offering, with its shares jumping 122% on the first day of trading. The strong debut reflects investor enthusiasm for the growing aesthetics market and the company's innovative...
Endpoints News
Deals•Feb 5, 2026
Angitia Biopharma Secures $130M Series D to Advance Musculoskeletal Drug Pipeline
US-China biotech Angitia Biopharmaceuticals announced a $130 million Series D financing to support three biologics in clinical testing for musculoskeletal diseases. The funding will advance its pipeline, including a candidate that previously fell short at Ultragenyx, highlighting investor confidence in...
Endpoints News
Deals•Feb 5, 2026
Generate:Biomedicines Files for IPO to Commercialize AI-Driven Drugs
Generate:Biomedicines, a Flagship Pioneering-backed AI bio startup, has filed for an initial public offering just nine days after dosing its first patient in a Phase 3 trial. The filing signals the company’s move to raise capital and bring AI-driven drug...
Endpoints News
Deals•Feb 5, 2026
Eikon Therapeutics Announces IPO Amid Valuation Cut
Bay Area biotech startup Eikon Therapeutics is preparing for an initial public offering, shifting from its $1 billion fundraising history. The analysis highlights a significant valuation cut as the company moves toward going public, marking a major event in the biotech...
Endpoints News
Deals•Feb 3, 2026
Menlo Ventures and A16z Back AI Startup Phylo in Undisclosed Funding Round
Menlo Ventures and Andreessen Horowitz (a16z) have invested in Phylo, an AI scientist startup founded by Stanford researchers Le Cong, Yuanhao Qu, Kexin Huang, and Jure Leskovec. The funding round was announced on February 3, 2026, with undisclosed terms.
Endpoints News
Deals•Jan 29, 2026
Agomab Therapeutics Targets $182M Nasdaq IPO to Fund Fibrosis Pipeline
Belgian biotech Agomab Therapeutics announced plans for a Nasdaq IPO to raise approximately $182 million in net proceeds. The capital will support the development of its fibrosis drug pipeline, with the company aiming to sell 12.5 million shares. The offering...
Endpoints News
Deals•Jan 29, 2026
Premise Health to Merge with Crossover Health to Expand Employer Clinics
Premise Health, an advanced primary care provider, announced a merger with Crossover Health, which runs on‑site health clinics for large employers such as Google and Amazon. The combined company aims to broaden its employer clinic network and help control rising...
Endpoints News
Deals•Jan 28, 2026
Veradermics Targets $181.8M Net Proceeds in Upcoming IPO
Biotech firm Veradermics, developing an oral version of Rogaine, announced plans to go public and raise approximately $181.8 million in net proceeds. The proposed IPO will fund late‑stage testing and commercialization of its hair‑loss treatment.
Endpoints News
Deals•Jan 28, 2026
Cellares Secures $257M Series D Funding to Accelerate Global Expansion and Target 2027 IPO
Clinical-stage cell therapy manufacturer Cellares announced a $257 million Series D funding round to support its global expansion and commercial rollout. The capital will also fund preparations for a planned initial public offering in 2027, highlighting investor confidence in its...
Endpoints News
Deals•Jan 27, 2026
Boehringer Ingelheim to Acquire IBD Bispecific From Simcere for €42M
German pharma Boehringer Ingelheim has agreed to pay €42 million upfront to Shanghai-based Simcere Pharmaceutical for an IBD bispecific drug candidate, marking a new partnership in immunology.
Endpoints News
Deals•Jan 27, 2026
Wisp Acquires Sexual Health Startup TBD Health
Virtual women's health platform Wisp announced the acquisition of sexual healthcare startup TBD Health, expanding its tele‑health services. The deal, reported on Jan. 27, 2026, aims to broaden Wisp's offerings in women's sexual health.
Endpoints News
Deals•Jan 27, 2026
Insilico Medicine Secures $120M Drug Discovery Pact with Qilu Pharma
Insilico Medicine announced a $120 million partnership with Chinese pharmaceutical firm Qilu Pharma to develop cardiometabolic therapies. The collaboration will leverage Insilico's AI-driven drug discovery platform to accelerate the identification of novel candidates. The deal highlights growing interest in AI-powered...
Endpoints News
Deals•Jan 27, 2026
TRexBio Raises $50M in Series B Extension for Treg Clinical Development
Bay Area biotech TRexBio announced an additional $50 million to its 2024 Series B round, aimed at advancing its pipeline of regulatory T cell (Treg) candidates into clinical trials. The funding will support further development and expansion of its immunotherapy...
Endpoints News
Deals•Jan 22, 2026
Erasca Announces Upsized Public Offering of Common Stock
Erasca announced the pricing of an upsized public offering of its common stock, aiming to raise over $500 million. The offering, part of a broader $500M+ target for several biotech firms, was disclosed in a press release on Jan. 22,...
Endpoints News
Deals•Jan 22, 2026
BioMarin Veterans Launch New Biotech, Raise $82M for Rare Disease Drug Development
Former BioMarin executives have founded a new biotech focused on rare disease therapeutics. The startup announced an $82 million fundraising round to support development of orphan drugs. The capital will be used to acquire and advance promising rare disease candidates.
Endpoints News
Deals•Jan 21, 2026
Claim Health Secures $4.4M Funding to Streamline Home Care Payments
Claim Health, a health‑tech startup, announced a $4.4 million fundraising round to develop AI‑driven solutions that automate payment processes for home‑care providers. The capital will support product development and scaling, with investors not disclosed at the time of the announcement.
Endpoints News
Deals•Jan 20, 2026
Shionogi Acquires Pfizer's Stake in ViiV, Doubling Its Ownership
Pfizer announced it will exit the HIV specialist joint venture ViiV, which it co‑founded with GSK. Shionogi will take over Pfizer’s share, doubling its stake in the company. The move reshapes ViiV’s ownership and strengthens Shionogi’s position in the HIV...
Endpoints News
Deals•Jan 20, 2026
GSK to Acquire RAPT for $2.2B
GlaxoSmithKline (GSK) announced a $2.2 billion acquisition of biotech firm RAPT, securing its food allergy candidate. The deal was unveiled at the JP Morgan Healthcare Conference, marking a major M&A move in the pharma sector.
Endpoints News
Deals•Jan 20, 2026
Exciva Secures $59M Series B Funding to Advance Alzheimer’s Agitation Drug
Exciva announced a €51 million ($59 million) Series B financing round to fund Phase 2 testing of its candidate drug targeting agitation in Alzheimer’s disease. The capital will support clinical development and expand the company's pipeline.
Endpoints News
Deals•Jan 15, 2026
AbbVie Acquires Drug-Device Factory
Pharmaceutical giant AbbVie announced the acquisition of a drug-device manufacturing facility, expanding its presence in the medical device sector. The deal was reported on January 15, 2026, with financial terms undisclosed.
Endpoints News
News•Jan 13, 2026
FDA Requests Flu Vaccine Label Updates to Include Febrile Seizure Risk
The U.S. Food and Drug Administration has asked manufacturers of six seasonal influenza vaccines to revise their product labels to explicitly mention the risk of febrile seizures. The directive follows emerging safety data linking certain flu shots, especially those administered...
By Endpoints News
News•Jan 13, 2026
FDA Asks Lilly, Novo to Remove Suicide Warnings From GLP-1 Labels
The FDA has asked Eli Lilly and Novo Nordisk to remove suicide‑related warnings from the labels of their GLP‑1 weight‑loss drugs. The warning, added in 2022 after isolated case reports, is being reconsidered following a thorough review of post‑marketing data. The agency...
By Endpoints News
News•Jan 13, 2026
HHS Ousts Vaccine Injury Panel Members as Reshaping Takes Hold
The U.S. Department of Health and Human Services removed several members from the Vaccine Injury Compensation Program’s advisory committee, signaling a significant reshaping of the panel. The ousted members were appointed during the previous administration and faced criticism for their...
By Endpoints News
News•Jan 13, 2026
Trump Administration Appears to Have Ended Its US Trade Probe Into Pharma
The U.S. Department of Commerce has reportedly concluded its Section 232 investigation into pharmaceutical imports, effectively ending the Trump administration’s trade probe. The decision means no new tariffs will be levied on foreign‑made medicines, averting a potential price shock for...
By Endpoints News
News•Jan 13, 2026
VantAI Gets $80M and New Name; Dynavax Discloses It Had Pre-Sanofi Suitor
VantAI, a Roivant‑incubated AI drug‑discovery startup, closed an $80 million seed round and announced a rebrand to Proxima. The funding, led by existing backers, is intended to accelerate its proprietary AI platform for early‑stage therapeutics. The round underscores growing investor appetite...
By Endpoints News
News•Jan 13, 2026
Who’s Afraid of OpenAI?
OpenAI’s accelerating pace of model development is prompting businesses to reconsider direct competition. Companies are weighing whether to build in‑house AI, partner with OpenAI, or adopt alternative strategies. The debate intensifies as OpenAI’s products become more embedded in enterprise workflows,...
By Endpoints News
News•Jan 13, 2026
Marea Takes Drug for Acromegaly to Phase 2
Marea Therapeutics announced that its experimental drug for acromegaly has entered Phase 2 clinical testing. The move follows CEO Josh Lehrer’s October 2023 appointment and a review that revealed the compound had not met earlier expectations in pre‑clinical models. The Phase 2...
By Endpoints News
News•Jan 13, 2026
Novartis Licenses Radiopharma Asset From Chinese Biotech for $50M Upfront
Novartis has agreed to pay $50 million upfront to license a peptide‑based radiopharmaceutical asset from China’s Zonsen PepLib Biotech. The agreement, announced Monday, adds a novel imaging candidate to Novartis’ growing portfolio of radiopharma programs. Zonsen PepLib, a biotech focused on...
By Endpoints News
News•Jan 13, 2026
#JPM26: Day 2 at the JP Morgan Healthcare Conference
Amgen announced on day two of the J.P. Morgan Healthcare Conference that its experimental long‑acting obesity injection, Maritide, met primary endpoints in a Phase 2 trial. The data showed statistically significant weight loss and favorable safety signals in patients with obesity....
By Endpoints News
News•Jan 13, 2026
Sentynl Gets the First US Approval for Rare Copper Absorption Disease
Sentynl Therapeutics announced that the U.S. Food and Drug Administration has granted approval for its investigational therapy targeting Menkes disease, a rare and fatal genetic disorder of copper absorption. The approved product, branded Zycu..., is the first therapy in the...
By Endpoints News
News•Jan 13, 2026
Treg Biotech Sonoma Sheds Staff After Getting New CEO
Sonoma BioTherapeutics, a T‑regulatory cell biotech based in Sonoma, announced a workforce reduction across its Seattle, South San Francisco and remote positions following the appointment of a new chief executive officer. The cuts affect multiple departments as the company seeks...
By Endpoints News
News•Jan 13, 2026
Congress' Biotech Panel Pitches FDA Policy Upgrades to Help Performance
The National Security Commission on Emerging Biotechnology released a report urging the FDA to modernize its policies as biotech innovation outpaces regulation. The document proposes nearly two dozen specific reforms aimed at accelerating approvals while preserving safety. Recommendations include real‑time...
By Endpoints News
News•Jan 12, 2026
Pretzel Buys Rome and Its ‘Dark Genome’ Work
Pretzel Therapeutics announced the acquisition of Rome Therapeutics, a company specializing in “dark genome” research. The deal brings Rome’s functional genomics platform, extensive data sets, and scientific team under Pretzel’s AI‑driven drug discovery umbrella. Financial terms were not disclosed, but...
By Endpoints News
News•Jan 12, 2026
Nvidia-Partnered Startup Reveals AI-Generated Enzymes for Precise Gene Insertion
Basecamp Research, in partnership with Nvidia, unveiled a gene‑editing toolkit built from AI‑generated enzymes. The startup leveraged evolutionary deep‑learning models running on Nvidia GPUs to design proteins that insert DNA sequences with unprecedented precision. Early laboratory data indicate higher on‑target...
By Endpoints News
News•Jan 12, 2026
#JPM26: Novo Nordisk CEO Says Pharma Can Learn From the GLP-1 Compounding Boom
Novo Nordisk CEO Mike Doustad highlighted the explosive growth of telehealth‑driven GLP‑1 obesity drug sales. He noted that compounding pharmacies have rapidly scaled to meet demand, creating a new distribution model. Doustad argued that traditional pharma can learn from this...
By Endpoints News
News•Jan 12, 2026
At FDA's Request, Pfizer Helps Ease Shortage of Potential Autism Drug
The U.S. Department of Health and Human Services confirmed that, at the FDA's request, Pfizer has been enlisted to help alleviate a nationwide shortage of a drug being promoted by Robert F. Kennedy Jr.'s organization as a potential autism treatment....
By Endpoints News
News•Jan 12, 2026
FDA Lifts Partial Hold on Merck, Daiichi's Phase 3 Lung Cancer Study
The U.S. Food and Drug Administration removed a partial clinical hold on the Phase 3 trial jointly run by Merck and Daiichi Sankyo for a lung‑cancer therapy. The hold, originally imposed over safety and data‑integrity concerns, is now lifted, allowing...
By Endpoints News
News•Jan 12, 2026
Eisai Licenses Nuvation Lung Cancer Pill; Alnylam's Stock Dips After Sales Data Report
Eisai announced a licensing agreement with Nuvation Bio to develop a novel lung‑cancer pill, securing exclusive rights and an upfront cash payment plus milestone fees. The deal positions Eisai to expand its oncology portfolio amid competitive immunotherapy markets. Meanwhile, Alnylam...
By Endpoints News
News•Jan 12, 2026
AbbVie Jumps Into PD-1xVEGF Bispecific Race, Pays $650M Upfront to RemeGen
AbbVie announced a $650 million upfront deal with Chinese biotech RemeGen to acquire a bispecific antibody that simultaneously blocks PD‑1 and VEGF, marking its entry into the fast‑growing PD‑1×VEGF space. The agreement, unveiled at the JPMorgan Healthcare Conference, includes additional milestone...
By Endpoints News
News•Jan 12, 2026
Eli Lilly, Nvidia Sign Five-Year, up to $1B Deal for AI Laboratory
Pharmaceutical giant Eli Lilly and chipmaker Nvidia have sealed a five‑year agreement worth up to $1 billion to create an AI laboratory focused on drug discovery. The partnership builds on an earlier pact to construct pharma’s most powerful supercomputer, extending Nvidia’s hardware...
By Endpoints News
News•Jan 12, 2026
FDA Again Rejects Atara, Pierre Fabre's Cell Therapy for Epstein-Barr Virus
The U.S. Food and Drug Administration has again refused to approve Atara Bio’s EBV‑specific T‑cell therapy, a treatment developed with French partner Pierre Fabre for post‑transplant lymphoproliferative disorder (PTLD). The agency cited insufficient clinical data and unresolved safety concerns, prompting Atara...
By Endpoints News
News•Jan 12, 2026
Arkin Capital Raises $100M to Back a Dozen Early-Stage Biotechs
Arkin Capital has closed a $100 million third early‑stage biotech fund, aimed at backing 10 to 12 nascent drug‑development companies. The Israel‑based venture firm plans to deploy the capital across a portfolio of early‑stage therapeutics, focusing on innovative platforms and unmet...
By Endpoints News
News•Jan 12, 2026
#JPM26: Moderna CEO Bancel Talks Deals, Flu and RSV Strategy
Moderna CEO Stéphane Bancel told JPMorgan analysts that the company’s deals team has closed several partnership agreements in the first quarter, accelerating its pipeline beyond COVID‑19. He outlined a dual‑track strategy for the upcoming flu season, emphasizing a next‑generation quadrivalent...
By Endpoints News
News•Jan 12, 2026
Novartis, SciNeuro to Work Together on Preclinical Amyloid-Targeting Drug for Alzheimer’s
Novartis is committing $165 million upfront to license a pre‑clinical amyloid‑targeting program from SciNeuro. The partnership will jointly advance the candidate through IND‑enabling studies and later clinical trials. Both companies aim to develop a disease‑modifying Alzheimer’s therapy that can address the...
By Endpoints News
Deals•Jan 12, 2026
Eli Lilly and Nvidia Sign Five‑year, up to $1 Billion AI Laboratory Deal
Eli Lilly and Nvidia have entered a five‑year partnership valued at up to $1 billion to create an AI laboratory aimed at accelerating drug discovery. The collaboration builds on a prior agreement to build pharma’s largest supercomputer and will leverage Nvidia’s...
Endpoints News
News•Jan 11, 2026
Signal Pulse Poll: What's the Mood Going Into JPM?
Endpoints has launched a daily Pulse Poll to capture biopharma sentiment ahead of the J.P. Morgan Healthcare Conference 2024. The survey asks participants to compare current mood with last year, assess the 2026 risk‑reward balance, and identify the most critical...
By Endpoints News
News•Jan 11, 2026
Private and Public Biotechs Go on $4.9B Funding Spree Ahead of JPM
In the first full week of January, biotech companies collectively raised about $4.9 billion, marking a rapid funding surge ahead of the J.P. Morgan Healthcare Conference. Private‑stage firms attracted roughly $3.2 billion, while publicly listed biotechs secured around $1.7 billion through secondary offerings...
By Endpoints News
News•Jan 11, 2026
Biotech's 2026 Outlook: Six Questions for the Year Ahead
The 2026 biotech outlook hinges on six pivotal questions that will shape the industry’s trajectory. After a turbulent 2025 marked by regulatory shifts, financing volatility, and rapid scientific advances, stakeholders are reassessing strategies. Key themes include FDA reform, capital availability,...
By Endpoints News
News•Jan 11, 2026
Mirador Raises $250M, with Plans to Become an Immunology Powerhouse
Mirador Therapeutics announced a $250 million Series B financing round, led by top venture capital firms. The capital will accelerate its precision‑medicine platform aimed at immune‑mediated diseases. Mirador plans to broaden its R&D pipeline, establish new manufacturing capacity, and recruit leading...
By Endpoints News
News•Jan 11, 2026
Genentech CEO Says Pharmacy Benefit Manager Shift Will Save $70M
Genentech announced it will move its pharmacy benefit coverage from a major PBM to a privately‑held entity it controls, aiming to capture savings and increase transparency. The shift is projected to generate about $70 million in annual cost reductions for the...
By Endpoints News
News•Jan 10, 2026
Hair Growth Biotech Veradermics Files for IPO to Fund Oral Rogaine
Veradermics, a biotech focused on an oral formulation of the hair‑growth drug Rogaine, has filed an S‑1 to launch an initial public offering. The company seeks to raise roughly $150 million to fund late‑stage clinical trials and scale manufacturing. An oral...
By Endpoints News
News•Jan 9, 2026
How Merck Plans to Set a Buffer for Keytruda's Patent Cliff
Merck’s blockbuster immunotherapy Keytruda is approaching a major patent cliff, with its primary U.S. patent set to expire in 2028. To blunt the anticipated revenue erosion, the company is deploying a multi‑pronged buffer strategy that includes filing for patent extensions,...
By Endpoints News
News•Jan 9, 2026
Orca Adds $250M in Financing to Back Launch of T Cell Therapy
Orca Bio announced it has raised $250 million in new financing to support the commercial launch of its T‑cell therapy designed to treat complications from allogeneic stem cell transplants. The capital infusion comes from a mix of venture capital firms and...
By Endpoints News
News•Jan 9, 2026
Novartis to Build Fourth US Radiotherapy Factory in Florida
Novartis announced the construction of its fourth U.S. radiotherapy manufacturing facility, a 35,000‑square‑foot plant in Winter Garden, Florida. The new site is part of the company’s broader $23 billion pledge to expand domestic production across the United States. The factory will...
By Endpoints News
News•Jan 9, 2026
BioNTech, UPenn Team up for $50M Seed Fund
BioNTech and the University of Pennsylvania have announced a $50 million seed‑stage venture fund focused on mRNA‑based technologies. The fund will invest in early‑stage biotech startups, leveraging BioNTech’s commercial expertise and UPenn’s research capabilities. By targeting vaccine and therapeutic platforms, the...
By Endpoints News
News•Jan 9, 2026
Krystal Biotech Says It Can Deliver Native Protein to Cystic Fibrosis Patients
Krystal Biotech announced early data showing its mutation‑agnostic platform can deliver functional native CFTR protein to the lungs of cystic fibrosis patients. In pre‑clinical models, the therapy restored up to 45% of normal chloride transport and reduced inflammatory markers. The...
By Endpoints News
News•Jan 9, 2026
J&J Strikes Drug Pricing, Tariff Deal with the White House
Johnson & Johnson has become the latest pharmaceutical company to sign a "most‑favored‑nation" pricing agreement with the White House. The deal commits J&J to lower the list prices of a portfolio of high‑cost drugs for federal programs, including Medicare and...
By Endpoints News
News•Jan 9, 2026
Roche Returns to Chinese Biotech MediLink for Another ADC Pact
Roche has entered a second licensing agreement with Chinese biotech MediLink, this time to develop an antibody‑drug conjugate (ADC) that targets the B7‑H3 antigen on solid tumours. The deal builds on a prior partnership focused on earlier‑stage oncology assets and...
By Endpoints News
News•Jan 9, 2026
AirNexis Gets $200M to Test China-Derived COPD Drug
AirNexis, a Palo Alto biotech, announced a $200 million financing round to launch clinical testing of a chronic obstructive pulmonary disease (COPD) therapy derived from Chinese research. The capital, sourced from a mix of U.S. and Chinese investors, will fund Phase 2/3...
By Endpoints News
News•Jan 9, 2026
Speculation Builds About a Deal for Revolution Medicines
Speculation is mounting that Revolution Medicines, a mid‑stage biotech focused on precision oncology, is in advanced talks with one or more large pharmaceutical companies. Media outlets report that the discussions could lead to a takeover or strategic partnership, though no...
By Endpoints News
News•Jan 9, 2026
Enliven’s Phase 1 Leukemia Pill Data Look Competitive with Novartis and Terns
Enliven Therapeutics announced Phase 1 results for its oral leukemia candidate, showing response rates and safety comparable to leading therapies from Novartis and Terns. The data revealed a 45% overall remission rate and manageable adverse events across 30 patients. The...
By Endpoints News
News•Jan 9, 2026
Viking Gets Commercial Chief While Other Obesity Biotechs Sell; Novo's Uli Stilz Steps Down
Viking Therapeutics announced the appointment of Neil Aubuchon as its chief commercial officer, signaling a push to accelerate commercialization of its obesity and MASH drug candidates. The move comes as the company’s shareholders grow impatient for a strategic partner or...
By Endpoints News
News•Jan 9, 2026
Medipost Gets $140M to Take Korean Stem Cell Therapy Into US
Medipost, a Seoul‑area biotech, has secured $140 million to commercialize its allogeneic stem‑cell therapy beyond South Korea. The product, cleared for use in Korea since 2012, will now target the United States and Japan. The capital infusion will fund FDA and...
By Endpoints News
News•Jan 9, 2026
Gene Editing Pioneers Launch First Startup Focused on Custom CRISPR Therapies
A team of leading gene‑editing scientists has launched a new startup dedicated to developing custom CRISPR therapies for individual patients. The company builds on a landmark case last spring where researchers engineered a bespoke CRISPR treatment to correct a rare...
By Endpoints News
News•Jan 9, 2026
Aktis Lands Biotech's First IPO of 2026, Raising $318M for Radiopharmaceuticals
Aktis Oncology, a radiopharmaceutical startup co‑founded with Eli Lilly, debuted on Nasdaq, raising $318 million in what is being billed as biotech’s first IPO of 2026. The capital will fund the company’s pipeline of targeted cancer therapies that combine diagnostic imaging with...
By Endpoints News
News•Jan 9, 2026
OpenAI Brings ChatGPT to Hospitals on the Heels of Launching Consumer Health Tool
OpenAI unveiled ChatGPT for Healthcare, extending its popular conversational AI into hospitals and health systems. The offering follows the recent launch of a consumer‑focused health tool, signaling a broader push into clinical environments. OpenAI says the service will integrate with...
By Endpoints News
Deals•Jan 9, 2026
Aktis Oncology Lands Biotech's First IPO of 2026, Raising $318M
Aktis Oncology, a radiopharmaceutical startup partnered with Eli Lilly, announced its initial public offering on the Nasdaq, raising $318 million. The IPO marks the first biotech offering of 2026, positioning the company for growth in the radiopharma sector.
Endpoints News
Deals•Jan 9, 2026
Medipost Raises $140M to Expand Korean Stem Cell Therapy to US and Japan
South Korean biotech Medipost announced a $140 million fundraising round to commercialize its allogeneic cell therapy, approved in South Korea since 2012, in the United States and Japan. The capital will support regulatory approvals and market entry in these regions.
Endpoints News
News•Jan 8, 2026
Sanofi Calls Rejection of Potential MS Blockbuster 'Unexpected'
Sanofi announced that the FDA rejected its experimental multiple‑sclerosis therapy, labeling the decision unexpected. The agency raised substantive questions late in the review process, leaving insufficient time for Sanofi to amend its submission. The setback threatens the anticipated launch of...
By Endpoints News
News•Jan 8, 2026
Illumina Hires Eric Green as Chief Medical Officer
Illumina announced the appointment of Eric Green, former director of the National Human Genome Research Institute and a pioneering geneticist, as its new chief medical officer. Green will lead the company’s clinical strategy, regulatory affairs, and diagnostic product development. The...
By Endpoints News
News•Jan 8, 2026
Servier Launches VC Unit Focused on European Biotech Startups
Servier has launched a corporate venture‑capital unit with an initial €200 million ($233 million) fund to back European biotech startups. The vehicle will focus on early‑stage companies developing innovative therapeutics that complement Servier’s core therapeutic areas. By providing capital and leveraging its...
By Endpoints News
News•Jan 8, 2026
FDA Staff Cuts Mostly Didn't Impact New Drug Review Timelines, Analysis Finds
Despite thousands of staff cuts, retirements, and leadership departures at the FDA in 2025, the agency’s drug reviewers largely maintained their review schedules. An internal analysis shows that median approval times for new molecular entities shifted by less than one...
By Endpoints News
Deals•Jan 8, 2026
French Biotech Enodia Therapeutics Raises €20.7M with Pfizer Backing
Enodia Therapeutics, a French biotech founded in February, announced it has raised €20.7 million (approximately $24 million) to develop protein degrader technology. The financing was aided by pharmaceutical giant Pfizer, marking a significant early-stage corporate investment in the company.
Endpoints News
Deals•Jan 8, 2026
Beacon Therapeutics Raises $75M Series C Led by Goldman Sachs Alternatives
Beacon Therapeutics announced a $75 million Series C financing round to advance its vision treatment pipeline. The round was led by Goldman Sachs Alternatives, with participation from a managing partner of the firm’s life sciences team. The funding aims to...
Endpoints News
Deals•Jan 8, 2026
Boltz Secures $28M Seed Funding to Build Open AI Models in Biology
Biotech startup Boltz announced a $28 million seed round to develop open AI models for biology. The funding will support the creation of large language models that predict biomolecular structures, building on advances like AlphaFold. The round highlights growing investor...
Endpoints News
Deals•Jan 8, 2026
Servier Launches €200M Corporate Venture Capital Unit for European Biotech Startups
French pharmaceutical group Servier announced the creation of a corporate venture capital unit focused on European biotech startups, initially funded with about €200 million ($232.9 million). The new VC arm aims to back emerging biotech innovations, joining a wave of large pharma...
Endpoints News
Deals•Jan 8, 2026
Parabilis Medicines Raises $305M to Tackle Undruggable Proteins
Parabilis Medicines announced a $305 million financing round to develop therapies targeting undruggable proteins. The capital will fuel its platform to address challenging protein targets, highlighting strong investor interest in biotech solutions for hard‑to‑drug diseases.
Endpoints News
Deals•Jan 8, 2026
Vizgen Raises $48M in Series E Round to Expand Spatial Biology and Multiomics Tools
Vizgen, a startup developing spatial biology and multiomics mapping technologies, announced a $48 million Series E funding round. The capital will be used to accelerate product development and market expansion. The round underscores continued investor interest in biotech innovation.
Endpoints News
Deals•Jan 8, 2026
Alveus Therapeutics Raises $159.8M in Series A to Expand Obesity Drug Pipeline
Alveus Therapeutics announced a $159.8 million Series A funding round on Thursday, aiming to accelerate its obesity drug development and challenge market leaders like tirzepatide and semaglutide. The capital will support the company's push into the space dominated by MariTide....
Endpoints News